Tweet
This came out today in the online version of Medical Laboratory Observer printed magazine not out yet.
12/15/06 Avian Flu Update
As of press, the incidents of H5N1 in 2006 are 111, with 76 fatalities. On Nov. 25th, South Korea confirmed its first case of infected poultry in 3 years, resulting in the culling of 5.3 million birds. Scientists, however, believe they may have found a weakness in the virus. As Agence France Presse reported on Dec. 7th , a vulnerability in the loop of the protein tail could possibly be comprised enough to stop the virus from replicating. A new drug has shown promise as a potential frontline treatment. Peramivir, developed by BioCryst Pharmaceuticals, is in Phase 11 trials and should be approved within 2 to 3 years. On the diagnostic front, Nanogen was recently awarded a CDC contract to develop a unique multianalyte point of care assay for influenza. The product under development has been designed with yjhe company's currently used technology for cardio-infarction products, which deliver results in as few as 15 minutes. Used in conjunction with seasonal flu testing, the new assay would help lessen the impact of a pandemic through earlier diagnosis.
BioCryst Pharmaceuticals BCRX trade at 11.82 today up nearly 4% on volume 65% above normal
--------billyjoe
12/15/06 Avian Flu Update
As of press, the incidents of H5N1 in 2006 are 111, with 76 fatalities. On Nov. 25th, South Korea confirmed its first case of infected poultry in 3 years, resulting in the culling of 5.3 million birds. Scientists, however, believe they may have found a weakness in the virus. As Agence France Presse reported on Dec. 7th , a vulnerability in the loop of the protein tail could possibly be comprised enough to stop the virus from replicating. A new drug has shown promise as a potential frontline treatment. Peramivir, developed by BioCryst Pharmaceuticals, is in Phase 11 trials and should be approved within 2 to 3 years. On the diagnostic front, Nanogen was recently awarded a CDC contract to develop a unique multianalyte point of care assay for influenza. The product under development has been designed with yjhe company's currently used technology for cardio-infarction products, which deliver results in as few as 15 minutes. Used in conjunction with seasonal flu testing, the new assay would help lessen the impact of a pandemic through earlier diagnosis.
BioCryst Pharmaceuticals BCRX trade at 11.82 today up nearly 4% on volume 65% above normal
--------billyjoe
Comment